Jennifer Kim

I wanted to ask about the reauthorization process and how those conversations have been going?

you commented on expanding your U.S. manufacturing footprint, specifically for brenso and U.S., can you just talk about timing?

any update on what you've been seeing?

is there a way to think about the expected placebo rate in the 24-week trial and then also variability or standard deviation

can you just remind us your thoughts on the importance of the six-minute walk endpoint in the context of a Phase 2